Arcutis Biotherapeutics, Inc. (ARQT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Arcutis Biotherapeutics, Inc. (ARQT) closed at USD 26.41 on 2026-10-14, a change of +5.9 % over the past year, with a market capitalization of USD 3.66B.

Arcutis Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Arcutis Biotherapeutics, Inc. key figures

Previous close

USD 26.41 (2026-10-14)

1-year change

+5.9 %

Market cap

USD 3.66B

Enterprise value

USD 3.53B

P/E ratio (trailing)

132.27

P/E ratio (forward)

21.40

EPS (trailing)

0.22

EPS (forward)

1.36

PEG ratio

n/a

Price to book

16.57

Revenue growth

59.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.49

Employees

354

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Arcutis Biotherapeutics, Inc. and compare it with other stocks.